-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Hdl41VlOanaTVDtKWqI4/fD3cbUrxOLNqYOWZdhAIIdi5N46Gz7OPoe2mrDbQw2Q
 uIJ0OcqJravAysj7gaGZQA==

<SEC-DOCUMENT>0000950123-10-103156.txt : 20101109
<SEC-HEADER>0000950123-10-103156.hdr.sgml : 20101109
<ACCEPTANCE-DATETIME>20101109145757
ACCESSION NUMBER:		0000950123-10-103156
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101109
DATE AS OF CHANGE:		20101109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		101175851

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a57806e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): November&nbsp;9, 2010</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>LifeVantage Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Colorado</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-30489</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>90-0224471</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other Jurisdiction of <BR>
Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>11545 W. Bernardo Court, Suite&nbsp;301, San Diego, California</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>92127</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
Registrant&#146;s telephone number, including area code: <B>(858)&nbsp;312-8000</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">





<DIV align="center"><DIV style="FONT-size: 3pt; margin-top: 16pt; width: 40%; border-bottom: 1px solid #000000">&nbsp;</DIV></DIV>
(Former name or former address if changed since last report.)</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link2 "Item&nbsp;2.02 Results of Operations and Financial Conditions" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.02</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Results of Operations and Financial Conditions</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;9, 2010, Lifevantage Corporation issued a press release announcing its unaudited
first quarter fiscal 2011 financial and operating results. The press release is furnished as
Exhibit&nbsp;99.1 hereto and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
</DIV>
<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits" -->

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt">&nbsp;</TD>
    <TD valign="top" style="font-size: 10pt"><DIV style="margin-left:0px; text-indent:-0px">Press release dated November&nbsp;9, 2010.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 " SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: November 9, 2010            &nbsp;</TD>
    <TD colspan="3" align="left">L<FONT style="FONT-variant: SMALL-CAPS"><B>ifeVantage Corporation</B></FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">                                          /s/ Carrie E. McQueen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Carrie E. McQueen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Secretary &#038; Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a57806exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a57806a5780600.gif" alt="(LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIFEVANTAGE ANNOUNCES UNAUDITED FIRST QUARTER FISCAL 2011 FINANCIAL AND OPERATING RESULTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Company Reports $345k Record Operating Profit on Revenue Increase of $4.6&nbsp;million, or 247%<BR>
over Same Quarter Last Year</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Conference call scheduled for November&nbsp;10, 2010 at 1:30pm (Pacific); simultaneous webcast at</B><BR>
<u><B>www.lifevantage.com</B></u>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>San Diego</B>, <B>CA, November&nbsp;9, 2010</B>, LifeVantage Corporation (OTCBB: LFVN), the maker of
science-based solutions to oxidative stress, announced unaudited first quarter fiscal 2011
financial and operating results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company recorded approximately $6.4&nbsp;million net revenue for the three month period ended
September&nbsp;30, 2010, which represents a $4.6&nbsp;million, or 247%, increase over net revenue from the
same quarter last fiscal year, and a $2.0&nbsp;million, or 45%, sequential increase over net revenue
from the fourth fiscal quarter of 2010. The Company also recorded $5.4&nbsp;million in gross profit,
representing an 84% gross profit margin, an approximate 1% improvement over both first and fourth
fiscal quarters of 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Total operating expenses for the first fiscal quarter 2011 were approximately $5.1&nbsp;million, which
represents a $525,000, or 12%, increase over operating expenses from the same quarter last fiscal
year, and a $1.1&nbsp;million, or 27%, sequential increase over operating expenses from the fourth
fiscal quarter of 2010. The increase of $1.1&nbsp;million over last quarter is due to increased sales
commissions attributed directly to increased revenue, and to higher personnel costs, tied to our
increased support requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Along with recording our highest quarterly net revenue of $6.4&nbsp;million, the Company is also
reporting record operating income of approximately $345,000 in the first fiscal quarter 2011. This
$345,000 operating profit compares to an operating loss of over $3.0&nbsp;million for the same quarter
last year and an operating loss of $290,000 for the most recent fourth fiscal quarter 2010. The
improvement of $635,000 in operating income is due to a $1.7&nbsp;million increase in gross profit
offset by a $1.1&nbsp;million increase in operating expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are very pleased with our first quarter results,&#148; said David W. Brown, LifeVantage President
and CEO, &#147;They reflect the growth we saw at our recent Elite Academy in San Diego, attended by over
1200 distributors. We&#146;d like to thank all of our distributors, customers and employees responsible
for these record results.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call Information</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will hold a conference call on November&nbsp;10, 2010 at 1:30pm Pacific time (4:30pm Eastern
time) to discuss first fiscal quarter 2011 financial and operating results and provide an update on
its business. David W. Brown, President and Chief Executive Officer, is scheduled to lead the call
and will be joined by Carrie E. McQueen, Chief Financial Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The conference call may be accessed by dialing 888-452-4034 for domestic callers and entering the
pass code 2457343. The webcast will be available live via the Internet by accessing the Investors
section of LifeVantage&#146;s website at <u>http://www.lifevantage.com/investor-profile.aspx</u>. Replays of
the webcast will be available on LifeVantage&#146;s website for 30&nbsp;days and a phone replay will be
available through November&nbsp;15<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>, 2010 by dialing 888-203-1112 and entering the pass code
2457343.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About LifeVantage Corporation</B><BR>
LifeVantage Corporation (OTCBB: LFVN) is a dietary supplement company which markets and sells its
products through the network marketing, or multi-level marketing industry, and seeks to enhance
life through anti-aging and wellness products while creating business opportunities. The Company
offers only what it refers to as &#147;true&#148; products, which are products backed by science, in two
principal categories: a dietary supplement that combats oxidative stress and anti-aging skincare.
LifeVantage&#146;s centerpiece product is Protandim<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, a dietary supplement which has been clinically
proven to reduce the effects of oxidative stress as well as the progressive rate of cellular aging.
The Company also offers LifeVantage TrueScience&#153; Anti-Aging Cream, a scientifically-based,
groundbreaking and unique skin care product. For more information, visit <u>www.LifeVantage.com</u>.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="a57806a5780600.gif" alt="(LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Forward Looking Statements</B><BR>
This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148;
&#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148; &#147;anticipates&#148; and variations thereof,
identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and the
Company&#146;s actual results could differ materially from those contained in such statements. These
forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning
future events affecting the Company and involve known and unknown risks and uncertainties that may
cause the Company&#146;s actual results or outcomes to be materially different from those anticipated
and discussed herein. These risks and uncertainties include, among others, the potential failure or
unintended negative consequences of the implementation of the Company&#146;s network marketing sales
channel; the Company&#146;s ability to retain independent distributors or to attract new independent
distributors on an ongoing basis; the potential for third party and governmental actions involving
the Company&#146;s network marketing sales channel; the potential for product liability claims against
the Company; the risk that government regulators and regulations could adversely affect the
Company&#146;s business; future laws or regulations may hinder or prohibit the production or sale of the
Company&#146;s existing product and any future products; unfavorable publicity could materially hurt the
Company&#146;s business; and the Company&#146;s ability to protect its intellectual property rights and the
value of its product. These and other risk factors are discussed in greater detail in the
Company&#146;s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption &#147;Risk
Factors&#148;, and in other documents filed by the Company from time to time with the Securities and
Exchange Commission. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect events or circumstances
after the date of this document, except as required by law.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>###</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor Relations Contact:</B><BR>
Ioana C. Hone<BR>
(858)&nbsp;312-8000 Ext. 4

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">LIFEVANTAGE CORPORATION AND SUBSIDIARIES<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">For the three months ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">September 30,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,443,349</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,857,997</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,020,135</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">312,974</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,423,214</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,545,023</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Sales and marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,410,843</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,012,166</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,507,093</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,381,156</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">109,793</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">106,892</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,716</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53,298</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,078,445</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,553,512</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating income (loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">344,769</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,008,489</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,464,623</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(153,701</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in fair value of derivative liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,835,047</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,027,736</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total other income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">370,424</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,874,035</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">715,193</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,865,546</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income per share, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.05</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares, basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63,684,437</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55,634,601</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares, diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89,693,864</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,841,866</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a57806a5780600.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a57806a5780600.gif
M1TE&.#EA_``W`/<```@M3`4O408N4`(P50<Q5`\S4A(T41@V4!DX41\]52)`
M6"=$7"E&7RI(8"U*8S-0:#A4;#Y:<$)<<TEB>%%J?U1M@EITB5YWC&-]D6B`
ME&N#EF^'F7J0H'R2HGZ4HX&7IX2;JXF?L(RALH^DM)"EM9>KNYVPOZ"SPJB[
MR:[!SK#"T+S+V,'/V\/1W,G5X,O7X<W9XM#=YM+>Y]/@Z=SG[MWH[^'L\^;P
M]^?R^>GS^O'X^____S,`;5P`,G,`36T`:68`=&0`+FP`;```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````!+:Q!E$J)-T\A+:J!E.8````!4``-T`&@`$<90`
M&0`$<````````1E'<````!A3<!+;B)$`70`!-0```!E.8``+K!+:S)#I(!+;
M6)#I()$M@/___Y$M>)%B!@```=@,)I%AS@```````!E.8!8`/)?NR```````
M``@``)?LP)?NR!+@N!+@N-@,)A+;`!+@LAE.8``````!-1+;@)#V7)#V80`!
M-0```!E.8!+;7)%?L!+;Q)#I(``!-0``?A+;D("3GA+@>!+@?````!+;Q)#V
M7)#V80```!+@?!+@>!+;H!E.8!+@2)#I(```````?A+;U("3G@``?A+@?!+@
M6(#FXH#F.P!`!5Z"2````"'Y!```````+`````#\`#<`AP@M3`4O408N4`(P
M50<Q5`\S4A(T41@V4!DX41\]52)`6"=$7"E&7RI(8"U*8S-0:#A4;#Y:<$)<
M<TEB>%%J?U1M@EITB5YWC&-]D6B`E&N#EF^'F7J0H'R2HGZ4HX&7IX2;JXF?
ML(RALH^DM)"EM9>KNYVPOZ"SPJB[R:[!SK#"T+S+V,'/V\/1W,G5X,O7X<W9
MXM#=YM+>Y]/@Z=SG[MWH[^'L\^;P]^?R^>GS^O'X^____S,`;5P`,G,`36T`
M:68`=&0`+FP`;```````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````!+:Q!E$J)-T
M\A+:J!E.8````!4``-T`&@`$<90`&0`$<````````1E'<````!A3<!+;B)$`
M70`!-0```!E.8``+K!+:S)#I(!+;6)#I()$M@/___Y$M>)%B!@```=@,)I%A
MS@```````!E.8!8`/)?NR`````````@``)?LP)?NR!+@N!+@N-@,)A+;`!+@
MLAE.8``````!-1+;@)#V7)#V80`!-0```!E.8!+;7)%?L!+;Q)#I(``!-0``
M?A+;D("3GA+@>!+@?````!+;Q)#V7)#V80```!+@?!+@>!+;H!E.8!+@2)#I
M(```````?A+;U("3G@``?A+@?!+@6(#FXH#F.P!`!5Z"2`````C^`'<('$BP
MH,&#"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/("?J&$ER9,B3*%.J7,E1
M1XX8)T!DL&`!0P9S)VRPW,FSI\^0+F>0L/```0``!A`\R##CI].&)I]*W:EC
M!@@$!09HU1H```08.J:*'9C#AHVP8]-ZU$'#A*JL`P)P'>`5+%JU/G786"'"
MG$Z\@#'J:+&A@-RX6@L4,`"A1=3`5&N<J#"A!N3+$</J0"'!\-8!!1`8."`!
M+&:6(X4R.$#CM.N&-D`H`*`5@`(*)U*@$$&B]6N554DT8'WWMW&!.F)P,!H@
M`((**&I(CP$CQ_&40H?/*'[]M0X6&YC^!VC`P7?WE32$'S!]OB-WD3G>K\!@
M]&@$$M8?/D:X'V5)_>_Q1X,(J[$76(`%]4<1#F8Q^!=$.>`@(0[Q#32?8LU)
M4$)\"@XTD@TPM+`""RS$@`."()7TWT+%J4C2#@&R)<)PU:W(HHHPZ@>CB_UU
MZ.&.-DIDPI`GE(#"@["Q,.20*<2`W'P&-#?``QRDH((*5K:0GX<PJ&`""!N$
MR0$()JQ``Y+(@5@#FBS:$,.9=^EP`PTPK&#G"BW$4$.,;)V)7`YTKI#"H'C2
M\)X.,,QX@`HPS."HHS34L"59-M#@`@MWMC##B0ZQ)>*@*>`I*4&5^HD0H"U@
M22@,9TDT007^L%*0@64/I4<9K!FH\"0&4<HUBP0V92`L".;!V%8&$T30P+(/
M2##!!BD86A"()Z@@K4,YP(`""JS"6)8+*)3`@9@@E+#"F@:YI,()+IR5PPPJ
MB+`!!O1N`$(*>[8(`P@-`""""2<$?`+`*]Q`4%DSL+`;!^-R(,()K+;(G4LV
MI``F!C1M(((*,U0(J&[7$I2:Q3/52\(*K4+4W%$`,&"70S!@<%0!7HFP*UR'
M*;88`J5IAL,*%JCRF5PK&]#`!BL\UA8#$(B0,HLQF,.`!"@#>@(%$#"`P`&C
M'>`U!!68L*?(,V#0@`@UX-`"4:(9<)37#%10\&-"/0```@HPH$#^W@I`D(%C
M`MG0@CD4/*#U`5LCSC32G!Y4U61:NXV4`4Q7@!^@)DQ`-9ILH5"!`EZSC(!2
M&-2(8D%Q==7RRPPA*G-<`$@@@F87?K;5VSVS=8(%"L`UUV<%-(#!"17NL!<$
M"&20].D"Y9!"!0=@T,(-A&7-0`,03(!Q!1(PX/T$'&A)E@L5(``""RE0@+WV
M#&>`==X5G+`=<C/,:,`#$.2O_P3FN!"6#2:H@/6:58'M22!O#;``">8GLARL
M@`/=JURPN+<W"'R@!8EZ@`)0YJ'!@$`"RY*`!38P+@'NS0(G,!3S!,*5KKC,
M1PF*&6VZ(CN2U*Z%<CF*`7IV`Q5DH'?^P-/95N32@`Q4IWDQ*)^&8#B0`4'`
M7VE3P><D4($,:"Q@?7%?`Q00`1`P,`<L*-\&3K"!J6$`!"?`4PI$@*R\92`%
M-]!,_1I@``R,:P,?,(<>3>"D'=2`!%FCHKU*,#`1?,`"!TP@\1+4`@A>KP(<
M,-*@2G#([D&`!!;;H@H>5!413$`I%D`CGE10@@U\3@%O?)I"AG@W`[%(AJJ+
MP.Q&`B7:P(YFN*L.##;0+[H$(#0->,`#WN*[`BA`!%O"`0<:P(`-Y&!2CB.,
MUJJ3@Q8@2P1FLDY)<)""##2`9RC(3[8J8``+_!`")>B823Z4`@G8)GS:%(H"
M$&`B#KUH(#;^0`$&X@<#"MGS72:0`-XL4"P=*%-K?E/G7;(50-*04),&\]8)
M)'``\O230\9Z'N4V`#B&S&5U*QP(+.DB2QMB@&;-04`$Z"6L#!"+!AQX`%QL
M4X%[8>H$$,39#CFX@QRH@*(48`'S<G`U!52`0^^B@3T3]"YS0$`!%NA83V$P
M`0.H`@(2@&/Q/'2#%4Q@:B+``8SDN9ZM)D@O,U#J/3WD0-XUX`-WN0$)]E:!
M="I(3C'XP`.".0L%J"`_.IAHWQ9H5ABIC7</^``#5WD8D#XD9E("0$EA!*7F
MC"<#N0%5"W[&.[@@0($M6),-9K`"$,@T+L;LC69B@`&FS6XA-'#^:@-`@!:]
MP-`E*>`=!#B8K0DL!@(<4*?C8+JW#?AF7Z!;+'\*:Y#T'+`"8AVK$D'@`FAV
MT*<8*(HQ.2BG###@`1M@@761@X,2/%<%*T0,713@RH6P``.6K1GM>`4[6:KU
MF?$AP0,,4!M9S@\MV:+/3/\F3A`\%0/C)4@+6AN!%&0F!OQ"0$ZFZEL#4."O
M"'+)";Y:`1@(9%_:"6GK@(8`",0@+#[5&P;^RI`<E*"JMN'M#`2*FP0C)V9,
MHRU##J,5]HIX!S*L30TI>]*5R3*ZR-%!9VZWP`"Q8,EQ><`).*6#%4Q1J!D.
M:!$+"IOG^<M0O44``\QAXQOSL@$I2,W^7`^@W(JP138,.!*B-A"[G*RP*J:-
ML4YJ4(*]@0#)"=&!"`XX`0HMA,<#\/%C7T>7(5>YR%VY#Z"KTKO#-&`%S-7+
M!F9A602(@(&QT2`R$62#'TK`!(!&SEE+4LT,`,"(+J'J#DO`O#=#H`$D4'-R
M?YSD%;DDH`@@P5E44%4"W]FG%MCN66*0`0-,8)$*H24&]J:ET]E.T3!C=.Q>
M^VC#1)H$@!:<V^12@`HH%$@DT2\`<K@!]@26`I]M\XV[9P%,G[4LE7I46F\@
MH0>^VC&]+6?2&((#$AR0ML'9=:?,0@-]GZE!&_:T#8@*@0,0BXD><L%R_'J#
MO53@U0/_4;K^9E!&!A#/VI_!=D."W&AN7RB'DB;5"8YR&&(]TRSXE9#SW%F;
M>M]EEP>`@'@/D@,4(&"VVVD1#F8@HG"5`&"ARI,*.```Z<7ZD^U>80XRU\RQ
MKEG>Z=)!#4*TKB55*T\S"*#Y:)">>4ZX5C/R*PYH@(*J?CI.'<*!")Y*9I1O
M1>4,@:R09]EMF(>5(#4`@2U!4P$\?N#Q(&"8Y+V9E:X\>Z$GT-JGTT6#\ED@
MG"*S@0H^(,##(6YT#(A`!1!9]6K'H*K!O?.&NYYP-M^%33V=P0F0=;C1(2YO
M8*L`'<MC%;RE`/<)`>!353!W$WQ3!"R`0:/T37U'03@"R6,N0:[^W5Z%"+[E
M\_6,9`\_D!K0V;(#F$4$UB\!"$1`F,)\/P*(%H`(G"!.5C8`@0N2+0W^;:&Z
MEP'Z$P$30`$&J#GZLT6M]TPP4#[E(7M?M0%>IW#)UP(B($#XXRP'*`$2\'Y/
M-3H<4`/%IP#'!Q$V<`(1P`#,-P-]]EEC`@(P&(,R*(,6\$T5$$>KE'+=EQ#?
MMVWA=Q@QUT09X&V-Q3(TESI$:%D10&NU!6'.=B33D@('\``B8!Z=,VTE-D(@
M0`)<"`(?D`$49!32PX#E<W&M,WL26'M@=V.>!'P6\`$B``(BD$7NDS4@*()7
M08+(AQ``%`%R)Q2BT2P<J#D<6(@<R'[^$E`4!W"#?M=C.X@0WQ<`2T1DGE%_
MX$80-.!JMF.$1Y$ZL+,R-(-.M64\*\!,7J1J0$9G%2!49($"%K`U5=(H_O1,
M<Y<P)\`K8QAF9L@B:#B!MI<0.6!@)08"*[`I^'5S,U`G((!]+R4">_-V#C$@
M&K2"<W4W\W2-\^0]>[.-\X1Z%J!*!L%]/Q:)D[@#+Q<702@0-4!UOC,+#[!^
M\-B!$="!'(A5[;=B"<)LG\5BS8,"R-,;'@(>6\0![;)4?\*`BF=UV2)0Y0$5
M:*AKO^@X*?!)ES0#-U`A*D*+DW$`(8@#SF<`7H1Q.P(#&U<P-6`"6L,!U8(E
M5]*2+OF2>,+^/(@&>`M!CK0F$.=HB8!6`R*P;E(B`2\X@W(HE.7B`@9A`W,U
M`<*&%C0``M?#4SWE.0H@`?P8:/73>K'&D,42:+/'`1"YACK``7F#`5B6(!VD
M`A9@`"&X<W54;:V#7<I&`YF'`.DTBV5QC'B)7RLTDX]X$#:)%CF9CCMP`R<P
M;J`17,?(:AFY5F3!`D^U`0PT'\]1+$AY:QFPE0A1?&3)@)_$`7LH,EWYE0B2
M`Q0PE;G6.F@)DF>Q8+$C9ZV#E!&@9_E4<240,AO!%4=!DPJQ8#,U63O``LUF
M9/C!5C,P;K_4&-`4%4&2+C:P`0IP>3N@=QH$>LA1`^=T?S="DO_^]DROMW8.
M&8%J1B,Q,F,,8`%8ME:/H0,:]8#Y-#HK]IG(,1E9,0LH8P,LD&P8$'(<@9NV
MP3J!IVU+")B\0C3WL24C<0/[U6DF8)LB4P-O@B(N`4C`91V$T3>NE(E,@YW1
MYD`RDXM4Y9UG")YJ&",P\%06T`+H=BHE@'V>Z1(L4%5=Y)_I8DW:M4'+UFP2
M`&TLHC*XR5[/Y!(_.A*)^6$`>I./%B6@4:`=I`.\8X1(@WMZ04HH@(..LP-2
M!%6&\CQQ8U:9V#<:&FB$Z5L*"0,"!0)CPXLB2E8&4EN(8J(HRCQ-^4V>"2,V
ML'$HI$+I\BZ#ME=]M4E^-%<*L(O1)I+^`G$877%IU9>HZL1R]3=JYDA?)(5,
M!G$",M4<QA1>$D-4GU,!*:!]QA)3$,!\>R>*(D,#9Q96<7)6,&`.1D%@XX0`
MYG"F"D%4I;D!89$>#U!6PW5>M8:6=S@0231/LG,BZ8D#+,`!WT4OW\1!Q[.(
MU!EH98$N'@4\\S@!A&B(AEA7U20S,(<?TH:DEFA=S-8OEMH`-64F#:<M`B@:
M"#`!FY1A194!]_D`%M!>+B90%1`#Q;,?!K5W;C.F9<B@CM.5@5,"=@-'AY(#
MGV-!Q,H?P$E'"!""9*$"6*@`&$`"*O`F-,`"I30!>2,"F62C,'(#8@E5F,8G
MU60.&5`"#6'^.UJ1%&UC`#([LTG!`""PK>M&4MYZI$!XB06!`Y,Q?Y8ZE2X5
MAQR079)#.;6)(M8TE2(PCW.:(,^C``^03AA96^\R&7N#E6$6J]_)`!P0.)P!
M`"!0(TNJ`P86-\S7(R#R0:KPJ_BT>T_%`!.0`1\0>6`(`?BC/!:X+/8V$E*$
M/1S``N#H$M0#`IIC#B3QHP>!:*ECA)]AA+"*LT8FJ4=J2T<V<GF6.J`H&NA'
M%W>SM`DA5T7Q2?$S7B[`2^UJ+1@EI/"B/MC3EIP)J[3"BZ49MC`21JU)(8O[
MHV%T`*C43\4*`R7`+')JFPZ4`;EZ`)R(.'ZC5'.T08`5C`)U-M/^LTXC@0/[
M@CQ+(:1F@7NV0VXTY[@LHP!D)D.XU#0FQ;SVX;/-E3G\)26_HUX[I%K1M@*N
M9@`*P`$G%DT?P```\``8`+)VLBX@\(H(,,!TEHNO=P`?@)D#&X'EEWE!MP$E
ML"XE(`(E<&*!53X[Q`$F$"J"4DK(,UL@`#T@4+CO(A.48:V-5P+^,U9.*70&
M2E2?1!HKJP)V$BX0=`!Q4P(GLA<9?`(',;ZJPXD^R8F!BK,LH[XX:0'L&SON
MRW_$6P&JT"N6A7[!4U-F&VCIP34:@GQ1*H!Z0T7T4@$4D(@0,#Q3)[MN\DE>
MVSI<)X&!4Z'?147<PS].DAPE8`%9`P'^%%`3^]1^S6(.*V`"%&!QM1MZ33<P
M(;P",?`7B+(<$7!$24:\O-,W$R#(%C`!?XP!)7!$^12'+&L0W'C*J'S*5/@2
MWK6-%'"3.U"AVUA7>_@N)%`!&I05.J,8"I!`)."6&ZH">Y4K-C;&<QM,W.@W
M\I,H1U-=;H(!EP2?R*%/$@`"I));UK-%J??`R!$#)0#-VKA7>],`%!`^/03-
M)+#(3%6+:A4GP%E._:MJ+]''<]O+&N0]RJRO_[,;:'008B)Y`!W0`4V,8H=3
MDO?+380"D<<P)=!1RZ4DIE04>-,L&6`"A,L\DOQ'(*`"ZBQR8V4Q&.#)SG)&
M\I.]+7`R?R'^>@TMS0)!`^NR`OS7`B;``9W<>!9MH,:*4XCD?E6$L2KDTB<P
M=!2AJ6HIL,8#`SHMC]IS+\(5."L0,+K27&SW*&PWU8KJ*!Q2*FQG%I12U0_W
MEI52)RV))S,P<;RF%VL24GI!`S'@`BW0`B[P)F>A&?CF(=_[$/B6G&7!UAAT
M)GH=UF^-066]KW<M,B*9&LZI`#K*5(#2UF\=UVF=(#90`Z:R:CQRV>@)I(>"
M(YUR<]]K%H0:=IF1E_Q:I1KAO1AU*GEMD*?B`F8"CND"M!5`MT(-K7?)N$1G
MUNUQVKL-$DCY1I*"=\I9%1;P7<;%:[V=W.V1&A2U%"80,<,-*"J#D,BH=++*
M?=W8[3@SP`%9<QL6K`(8%`/)^-0@T%KEF4+(G=WJ?1IZ@0(;`$*58R\D\'2&
M%-+>0P$BT)?KO=_=D2URRS5X0[4:I`"CD3SXDM[\G>"`03&D=8NX_$U')T(@
EP"USK>`6OMRT&`,/9`$1,`NCTP#:(P(MH$((?N$F?N(2$1``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
